Due to accumulating evidence indicating that certain molecular characteristics (including CIMP, BRAF mutation, KRAS mutation, and MSI status) have diagnostic, therapeutic, and prognostic significance in CRC personalised medicine and incidences that vary considerably among different ethnic or geographic populations, this study determined the frequency of CIMP, BRAF/KRAS mutation, and MSI in a unique ethnic Chinese population-based CRC cohort. This evidence concerns the gene BRAF and colorectal carcinoma.